Resminostat maintenance for advanced cutaneous lymphoma: RESMAIN study

2 Views
administrator
administrator
08/09/23

Maintenance therapy options for cutaneous T-cell lymphomas could be improved. Here, Rudolf Stadler, MD, PhD, of the University Medical Center Minden, Minden, Germany, discusses the RESMAIN study (NCT02953301), investigating resminostat as a maintenance therapy for advanced mycosis fungoides or Sรฉzary syndrome. This video was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next